This is a working overview of refrigeration, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-14. Anything still debated is marked as such rather than presented as settled.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid form |
| Purity assay | 95 percent or greater by RP-HPLC | Typical research-grade specification |
| Storage temperature | 2 to 8 degrees Celsius | Formulated solution, do not freeze |
| Common analytical method | LC-MS with peptide mapping | Identity and impurity confirmation |
| Primary degradation routes | Deamidation, oxidation, aggregation | Tracked in stability programs |
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
=== Solution === Unmodified chitosan is generally insoluble in pure water, but dissolves in dilute acidic solutions (pH < 6). It is insoluble in most organic solvents. This is because chitosan behaves like a strong base, with its primary amine groups having a pKa of about 6.3 for the reaction R-NH+3 ⇌ R−NH2 + H+. When enough hydrogen ions are present, the amine group becomes protonated, giving it a positive charge. This allows water molecules to better "pick up" chitosan in the form of a water-soluble cationic polyelectrolyte. Chitosan readily forms soluble salts with many organic acid anions, including formate, acetate, lactate, malate, citrate, glyoxylate, pyruvate, glycolate, and ascorbate. Chitosan can also be dissolved in aqueous CO2, which is useful for minimizing excess acidity. The solubility and pKa of chitosan is affected by DD%. How the acetyl groups are distributed on the chain also matters. As a polyelectrolyte, the protonation behavior of chitosan is best described by Kachalsky's equation.
=== Economic solar panel === The MAXXUN project was to develop a system of disruptive solar cells based on the luminescent solar concentrating (LSC) technology, in order to lower the investment for a solar energy system by more than half. Altran Technologies consultants have worked during a year with the award-winning team to increase the surface area of the panel from 2.5 cm2 to 10 cm2; to apply an absorbing and dispersing layer on this extra surface area; to optimize light power under different conditions; to build a demonstration model and to identify potential partners.
=== Australia === Powdered alcohol is illegal in the state of Victoria, as of 1 July 2015. As of the Liquor (Undesirable Liquor Product - Powdered Alcohol) Amendment Regulation 2018, made under the Liquor Act 1992, Powdered Alcohol in Queensland was banned and pronounced illegal. The NSW Government also recognises powdered alcohol an undesirable product under the Liquor Regulation Act 2018.
Sources: en.wikipedia.org
==== Voice acting ==== Shawn is a voice actor for animated films and television series, including the Toy Story franchise, Monsters, Inc. (during the outtakes in the closing credits), Kingdom Hearts III, The Incredibles, A Goofy Movie, Family Guy, Happily N'Ever After, Tom and Jerry: Shiver Me Whiskers, Regular Show, BoJack Horseman and Animal Crackers. Shawn said that Toy Story director John Lasseter might have seen both My Dinner with Andre and The Princess Bride and seen him as "excitable" like Shawn's character, Rex. During production of The Fox and the Hound, Shawn was originally cast as Boomer, but dropped out and was replaced by Paul Winchell. In Cats & Dogs: The Revenge of Kitty Galore, he replaced Jon Lovitz as the voice of Calico. He also voiced Mr. Mustela in The Addams Family 2.
The election was a rare victory for conservatism and nationalism in Thailand, marking its first victory in the 21st century. Bhumjaithai was seen as benefiting from nationalist sentiments after Thailand's recent clash with Cambodia. While the other two major parties performed respectably, they ultimately fragmented the centrist and progressive vote. Anutin formed a coalition government with Pheu Thai and was re-elected prime minister on 19 March 2026. The conduct of the election remained subject to legal challenge, with the Constitutional Court due to rule in September 2026 on whether codes printed on the ballots breached the constitutional guarantee of voting secrecy.
Their half-lives range from years to millions of years and as alpha emitters they are particularly radiotoxic. While there are proposed – and to a much lesser extent current – uses of all those elements, commercial-scale reprocessing using the PUREX-process disposes of them as waste together with the fission products. The waste is subsequently converted into a glass-like ceramic for storage in a deep geological repository. The duration that radioactive waste must be stored depends on the type of waste and radioactive isotopes it contains. Short-term approaches to radioactive waste storage have been segregation and storage on the surface or near-surface of the earth. Burial in a deep geological repository is a favored solution for long-term storage of high-level waste, while re-use and transmutation are favored solutions for reducing the HLW inventory. Boundaries to recycling of spent nuclear fuel are regulatory and economic as well as the problem of radioactive contamination if chemical separation processes cannot achieve a very high purity. Furthermore, elements may be present in both useful and troublesome isotopes, which would require costly and energy intensive isotope separation for their use – a currently uneconomic prospect. A summary of the amounts of radioactive waste and management approaches for most developed countries are presented and reviewed periodically as part of a joint convention of the International Atomic Energy Agency (IAEA).
== Conjugates == Attaching other hormones such as estrogen, thyroid hormone (T3), and dexamethasone to GLP-1 or glucagon restrict the activity of the attached hormone to cells that express GLP-1 or glucagon. GLP-1 and amylin receptor agonist conjugates have also been tested in preclinical trials.
Sources: en.wikipedia.org
==== Wound healing ==== Stem cells can also be used to stimulate the growth of human tissues. In an adult, wounded tissue is most often replaced by scar tissue, which is characterized in the skin by disorganized collagen structure, loss of hair follicles and irregular vascular structure. In the case of wounded fetal tissue, however, wounded tissue is replaced with normal tissue through the activity of stem cells. A possible method for tissue regeneration in adults is to place adult stem cell "seeds" inside a tissue bed "soil" in a wound bed and allow the stem cells to stimulate differentiation in the tissue bed cells. This method elicits a regenerative response more similar to fetal wound-healing than adult scar tissue formation. As of 2018, researchers were still investigating different aspects of the "soil" tissue that are conducive to regeneration. Because of the general healing capabilities of stem cells, they have gained interest for the treatment of cutaneous wounds, such as in skin cancer. Stem cell therapy has also been investigated for hair follicle regeneration. A clinical case report demonstrated improvement in hair loss following COVID-19 vaccination through combined administration of autologous CD34+ hematopoietic progenitor cell fraction and umbilical cord blood-derived mesenchymal stem cells (UC-MSCs), with progressive recovery of hair density observed over 12 weeks of treatment without significant adverse effects.
=== Stabilization that provides partial support or protection === Structural weakness and damage must be supported in textiles, especially areas such as the top of tapestries and the shoulders of garments
Bali in Indonesia Bengaluru the capital of Karnataka, India Chennai the capital of Tamil Nadu, India Chiang Mai in Thailand Loma Linda, California in the United States Shashamane in Oromia Region, Ethiopia Varanasi in Uttar Pradesh, India
Both NAD+ and NADH strongly absorb ultraviolet light because of the adenine. For example, peak absorption of NAD+ is at a wavelength of 259 nanometers (nm), with an extinction coefficient of 16,900 M−1cm−1. NADH also absorbs at higher wavelengths, with a second peak in UV absorption at 339 nm with an extinction coefficient of 6,220 M−1cm−1. This difference in the ultraviolet absorption spectra between the oxidized and reduced forms of the coenzymes at higher wavelengths makes it simple to measure the conversion of one to another in enzyme assays – by measuring the amount of UV absorption at 340 nm using a spectrophotometer. NAD+ and NADH also differ in their fluorescence. Freely diffusing NADH in aqueous solution, when excited at the nicotinamide absorbance of ~335 nm (near-UV), fluoresces at 445–460 nm (violet to blue) with a fluorescence lifetime of 0.4 nanoseconds, while NAD+ does not fluoresce. The properties of the fluorescence signal changes when NADH binds to proteins, so these changes can be used to measure dissociation constants, which are useful in the study of enzyme kinetics. These changes in fluorescence are also used to measure changes in the redox state of living cells, through fluorescence microscopy. NADH can be converted to NAD+ in a reaction catalysed by copper, which requires hydrogen peroxide. Thus, the supply of NAD+ in cells requires mitochondrial copper(II).
==== Absorption, bioavailability, and levels ==== The oral bioavailability of progesterone is very low. Studies using IA have generally measured the bioavailability of oral progesterone as less than 10%, with one study reporting values of 6.2 to 8.6%. However, these values are overestimations; a study using LC–MS found that the bioavailability of oral progesterone was only 2.4% relative to vaginal progesterone gel. Moreover, this was not relative to the standard of progesterone by intramuscular injection, which has much higher bioavailability than vaginal progesterone. The very low bioavailability of oral progesterone is due to the fact that it is poorly absorbed from the gastrointestinal tract and undergoes massive metabolism, resulting in almost complete inactivation during the first pass through the liver. Because of its poor oral bioavailability, very high doses of progesterone must be used by the oral route to achieve significant circulating progesterone levels. In addition, oral progesterone today is always micronized and suspended in oil. This improves the bioavailability of oral progesterone significantly compared to plain milled progesterone, and allows for it to be used at practical doses. When the term "oral progesterone" is used, what is used clinically and what is almost always being referred to, unless noted otherwise, is micronized progesterone suspended in oil. Micronization is the process of reducing the average diameter of the particles of a solid material.
Sources: en.wikipedia.org
Reversed-phase high-performance liquid chromatography is the standard approach, separating the main peak from related impurities. Ultraviolet detection near 214 nanometers captures the peptide backbone. Mass spectrometry is then used alongside chromatography to confirm identity and detect covalent modifications.
Cycling between frozen and liquid states concentrates the peptide at ice interfaces, which favors non-covalent association. The resulting aggregates may be invisible to simple assays yet alter recovery and apparent potency. Limiting the number of cycles and aliquoting before storage are common mitigations.
Tryptophan and methionine side chains can undergo photo-induced oxidation, so amber glass or opaque packaging is typical. The effect is gradual and depends on wavelength and exposure time. Light protection is usually specified for both solid and solution forms.
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.